Cost‐effectiveness analysis of human papillomavirus ( HPV ) genotyping strategies for management of HPV ‐positive women in cervical cancer screening
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70344 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Kelsi R Kroon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Early Detection of Cancer, Papillomaviridae. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission.
Abstract (Originalsprache)
In 2017, the Netherlands introduced primary human papillomavirus (HPV)‐based screening with cytology triage, which increased colposcopy referrals and low‐grade lesions detected. In 2022, HPV16/18 genotyping was added for women with borderline/low‐grade cytology. Triage with HPV genotyping may better balance screening benefits, harms, and costs. Therefore, we evaluated the cost‐effectiveness of 19 triage strategies based on net monetary benefit (NMB) at cost‐effectiveness thresholds of €20,000 and €50,000/quality‐adjusted life‐year (QALY), with the highest NMB indicating the most cost‐effective strategy. Triage tests included 16/18 genotyping, 7‐type (16/18/31/33/45/52/58) genotyping, and cytology (high‐grade squamous intraepithelial lesions [HSIL]: moderate/severe, atypical squamous cells of undetermined significance [ASC‐US]/low‐grade squamous intraepithelial lesions [LSIL]: borderline/low‐grade, negative for intraepithelial lesion or malignancy [NILM]: normal). Effects on cancer incidence and mortality were obtained by combining POBASCAM trial data with nationwide screening and cancer registries. Time since the onset of high‐grade lesion (cervical intraepithelial neoplasia [grade 2/3] [CIN2/3]) at baseline of the Population‐based Screening Study Amsterdam trial cannot be estimated from the data and was varied between 0 and 10 years. At a €20,000/QALY threshold, immediate referral for HSIL and 16/18‐positive ASC‐US/LSIL, and repeat cytology for 16/18‐negative ASC‐US/LSIL and 7‐types positive NILM had the highest NMB (€214.1 to €309.3/woman gained compared to referring all HPV‐positive women). At a €50,000/QALY threshold, immediate referral for all 16/18‐positives and/or HSIL, and repeat cytology for 16/18‐negative ASC‐US/LSIL and 7‐types positive NILM had the highest NMB if time since onset of CIN2/3 was greater than 2 years. Cytology combined with HPV16/18 and extended genotyping is cost‐effective for triage of HPV‐positives. Immediate colposcopy referral of all HPV16/18‐positives is cost‐effective at a €50,000/QALY threshold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Methodology, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
- Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Kelsi R Kroon, Johannes A Bogaards, Johannes Berkhof
Förderung
- European Commission
Zitieren
APA
Kroon, K. R., Bogaards, J. A., & Berkhof, J. (2026). Cost‐effectiveness analysis of human papillomavirus ( HPV ) genotyping strategies for management of HPV ‐positive women in cervical cancer screening. International Journal of Cancer. https://doi.org/10.1002/ijc.70344
Vancouver
Kroon KR, Bogaards JA, Berkhof J. Cost‐effectiveness analysis of human papillomavirus ( HPV ) genotyping strategies for management of HPV ‐positive women in cervical cancer screening. International Journal of Cancer. 2026. doi:10.1002/ijc.70344
BibTeX
@article{Kroon2026,
author = {Kroon, Kelsi R and Bogaards, Johannes A and Berkhof, Johannes},
title = {Cost‐effectiveness analysis of human papillomavirus ( HPV ) genotyping strategies for management of HPV ‐positive women in cervical cancer screening},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70344}
}
EUVIMED